Tag: 2025

The U.S. Food and Drug Administration (FDA) officially declared the shortage of Zepbound and its active ingredient, tirzepatide, resolved in December 2024 after manufacturer Eli Lilly ramped up production. However, throughout the year, many patients have continued to experience intermittent access issues, leading to persistent questions: **Is there a Zepbound shortage in 2025?**.

According to the American Academy of Sleep Medicine, millions of adults experience chronic insomnia, driving continuous research for novel treatments. In 2025, while no single breakthrough drug received widespread U.S. FDA approval specifically for standalone insomnia, significant updates on pipeline candidates and new therapeutic approaches shed light on the future of sleep medicine. This raises the question: what is the new insomnia drug 2025?

Over 332 million people worldwide experienced a Major Depressive Disorder episode in 2021, and for many, Prozac remains a vital component of treatment. But with new medications and therapies emerging, what is Prozac in 2025, and how has its role evolved in the modern landscape of mental health care?